Search
Search Results
-
BRAF-mutant microsatellite-stable rectal cancer with acquired KRAS mutation leading to drug resistance in liver metastasis
BRAF -mutant microsatellite-stable colorectal cancer (CRC), metastasized to distant sites, is associated with a poor prognosis. However, the BEACON...
-
The diagnostic utility of BRAF VE1 mutation-specific immunohistochemistry in ameloblastoma
Ameloblastoma is a benign, locally aggressive odontogenic neoplasm with variable solid and cystic morphology. On account of its histologic variety,...
-
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
Combination treatment with BRAF (BRAFi) plus MEK inhibitors (MEKi) has demonstrated survival benefit in patients with advanced melanoma harboring...
-
Add-on radioiodine during long-term BRAF/MEK inhibition in patients with RAI-refractory thyroid cancers: a reasonable option?
Dual modulation of the MAPK pathway with BRAF (e.g., dabrafenib) and MEK (e.g., trametinib) inhibitors has the potential to re-establish radioiodine...
-
Combined BRAF-Targeted Therapy with Immunotherapy in BRAF-Mutated Advanced Melanoma Patients
Purpose of ReviewTo review evidence on the efficacy and safety of combined BRAF-targeted therapy and immune checkpoint inhibitors in patients with...
-
AK2 is an AMP-sensing negative regulator of BRAF in tumorigenesis
The RAS–BRAF signaling is a major pathway of cell proliferation and their mutations are frequently found in human cancers. Adenylate kinase 2 (AK2),...
-
-
Differentiating BRAF V600E- and RAS-like alterations in encapsulated follicular patterned tumors through histologic features: a validation study
Differentiating BRAF V600E- and RAS -altered encapsulated follicular-patterned thyroid tumors based on morphology remains challenging. This study...
-
BRAF and RET polymorphism association with thyroid cancer risk, a preliminary study from Khyber Pakhtunkhwa population
BackgroundThyroid cancer, originating in the neck’s thyroid gland, encompasses various types. Genetic mutations, particularly in BRAF and RET genes...
-
Immune checkpoint blockade therapy for BRAF mutant metastatic colorectal cancer: the efficacy, new strategies, and potential biomarkers
BRAF mutant metastatic colorectal cancer has long been considered a tumor with a poor prognosis and a poor response to chemotherapy. Despite the...
-
Low incidence of BRAF and NRAS mutations in a population with a high incidence of melanoma
Reported rates of BRAF mutation in Irish cutaneous melanoma cohorts are lower than the reported international data. We aimed to assess the mutational...
-
Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned
Purpose of ReviewThe treatment strategy for BRAF -mutated melanoma remains unsatisfactory, although the advent of immune checkpoint inhibition has...
-
Structure-based prediction of BRAF mutation classes using machine-learning approaches
The BRAF kinase is attracting a lot of attention in oncology as alterations of its amino acid sequence can constitutively activate the MAP kinase...
-
Opposing roles by KRAS and BRAF mutation on immune cell infiltration in colorectal cancer – possible implications for immunotherapy
BackgroundThe immune response has important clinical value in colorectal cancer (CRC) in both prognosis and response to immunotherapy. This study...
-
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
No prospective data were available prior to 2021 to inform selection between combination BRAF and MEK inhibition versus dual blockade of programmed...
-
Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?
IntroductionThe mitogen-activated protein kinase (MAPK) signalling network aberrations in metastatic colorectal cancer (mCRC) generate intrinsic...
-
BRAFV600E mutational status assessment in cutaneous melanocytic neoplasms in a group of the Egyptian population
BackgroundMelanocytic neoplasms range from banal nevi to malignant melanomas. The genetic background has been extensively studied in the Caucasian...
-
BRAFV600E Metastatic Melanoma Journey: A Perspective from a Patient and his Oncologist
BackgroundThis article is co-authored by a patient with BRAF V600E metastatic melanoma and his treating oncologist.
Case DescriptionThe patient...
-
Targeted Therapy for Melanomas Without BRAF V600 Mutation
Purpose of ReviewImmune checkpoint inhibitors (ICIs) have revolutionized the treatment paradigm for patients with metastatic melanoma; however, there...
-
Impact of encorafenib on survival of patients with BRAFV600E-mutant metastatic colorectal cancer in a real-world setting
PurposePatients with BRAF V600E -mutant metastatic colorectal cancer (mCRC) have a dismal prognosis. The best strategies in these patients remain...
